Drugs / INBRX-106
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04198766 | Dec 2019 → Oct 2026 expected | gastric cancer, head and neck cancer, melanoma, non-small cell lung carcinoma +2 | Inhibrx Biosciences, Inc | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06353997 | Sep 2024 → Jun 2027 expected | triple-negative breast carcinoma | Providence Health & Services | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06295731 | May 2024 → May 2029 expected | head and neck squamous cell carcinoma | Inhibrx Biosciences, Inc | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INBRX-106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06295731 ↗ |
| Action | Activate | “hexavalent OX40 agonist antibody” NCT04198766 ↗ |
| Route | Intravenous | “INBRX-106 by intravenous (IV) infusion” NCT06295731 ↗ |
| Target | TNFRSF4 | “targets the human OX40 receptor (TNFRSF4)” NCT04198766 ↗ |